NervGen Pharma GAAP EPS of -$0.38

Seeking AlphaApr 17 23:54

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update

NervGen Pharma Corp. (NGEN.V), a biotech company developing solutions to treat nervous system damage, reported a net loss of $22.4 million, or $(0.38) per basic and diluted share for the year ended De

MT NewswiresApr 17 22:45

NervGen Completes $23 Million Bought Deal Financing

Yahoo FinanceMar 28 21:01

NervGen Pharma GAAP EPS of -$0.07

Seeking AlphaNov 10, 2023 01:04

NervGen Pharma GAAP EPS of -$0.08

Seeking AlphaMay 16, 2023 00:27

NervGen Pharma Appoints Michael Kelly as President & CEO

Seeking AlphaApr 10, 2023 21:23